Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: All Mtn Ski who wrote (234)	4/3/1998 4:15:00 PM
From: John R Resseger	Read Replies (1) \| Respond to of 548

San Diego Biotech Investment Fieldtrip June 2-5 Features Onsite Visits At 12 Biotech Companies Event Includes an Opening Address on HIV Research by Dr. Thomas Hope of The Salk Institute and a Scientific Panel Discussion With Researchers From The Scripps Research Institute SAN MATEO, Calif., March 31 /PRNewswire/ -- The fourth annual San Diego Biotech Investment Fieldtrip will be held Tuesday, June 2 through Friday, June 5 at the San Diego Marriott La Jolla Hotel. The invitation-only event gives analysts and portfolio managers the opportunity to meet with the management and scientific staff of 12 biotechnology companies at their facilities. This year, in addition to onsite visits at the companies hosting the fieldtrip, there will be presentations at the hotel by four additional companies. The program will begin on Tuesday afternoon with an opening address by Dr. Thomas Hope, assistant professor at The Salk Institute. He will discuss the latest research in HIV and the role of San Diego scientists in HIV research. On Friday, June 5 there will be a panel discussion at The Scripps Research Institute on ''Integran Mediated Cell Adhesion: Therapeutic Implications,'' by three researchers. The panelists are David A. Cheresh, M.D., Vito Quaranta, M.D. and Sanford Jack Shattil, M.D. The following 12 companies are hosting the 1998 program: Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) was organized in 1984 to bring a fresh approach to the discovery of new therapeutic drugs for treatment of cancer, AIDS and other serious diseases. Agouron has developed and mobilized an engineering approach to the design of novel synthetic drugs based upon the molecular structures of target proteins which play key roles in human diseases. Known as protein structure-based drug design, this approach uses innovations from a variety of scientific disciplines and substantially overcomes the technical barriers to traditional drug discovery. Alliance Pharmaceutical Corp. [Nasdaq:ALLP - news] is focused on transforming novel discoveries into innovative products. Three products based on Alliance's core technologies are in Phase II or Phase III clinical development: LiquiVente, a ''liquid ventilation'' drug; Oxygent(TM), a ''blood substitute'' being co- developed with Johnson & Johnson; and Imagent(R), an ultrasound contrast agent being co-developed with Schering AG, Berlin. Tom When are you going to try snowboarding? John